Mark Beer is a seasoned pharmaceutical executive with over 25 years of experience in the commercialization and development of products in the pharmaceutical, biotechnology and medical device industries.
He received a Bachelor of Science degree from Miami University in 1987. His education and skill at being able to solve problems while producing first-class service prepared him for a successful career in the biotechnology industry.
Marc has helped guide multiple start-up companies to grow into multinational, top-rated companies in the biotechnology and pharmaceutical industries. Marc’s first company was Viacell, a company he launched in 2000. At this company, he gained experience in the pharmaceutical and marketing world and went public in the Year 2005 with over 300 people employed at his company. Viacell specialized in collecting and preserving stem cells from the umbilical cord with the goal of using it to develop a variety of conditions and illnesses in the human body. In 2007, Marc sold Viacell for $300 million.
Earlier in his career, Marc also played a significant role in Genzyme, a company which specializes in the production of treatments that are used to improve the lives of people living with debilitating illnesses. He held several executive roles at this company and promoted the company’s product line, that served over 350 million people in underserved areas. Learn more: https://patch.com/massachusetts/boston/renovias-marc-beer-raises-42m-treat-womens-health-issues
Marc was also the founding chairman of Minerva Neurosciences Inc., a pharmaceutical company in the clinical research industry that is focused on the production of products for people with central nervous disease diseases. This company is currently working on several multiple late-stage clinical research trials, as well as developing experimental compounds in treating neurological diseases, such as insomnia, Parkinson’s disease, schizophrenia, major depressive disorder, and mood disorders.
In 2016, Marc partnered with Dr. Iglesia and Yolanda Lorie to found Renovia Inc., a Boston-based medical technology company that specializes in producing top of the line digital, diagnostic and medical devices for women with pelvic floor disorders. Pelvic floor dysfunction include urinary incontinence, pelvic organ prolapse and fecal incontinence and are estimated to affect 250 million women worldwide. One of the reasons women are not properly diagnosed and treated for pelvic floor dysfunction is because of the stigma associated with the disease. The goal of Renovia is to help remove the shame associated with the pelvic floor dysfunction and help women regain power and control of their pelvic floor muscle through the use of quality FDA approved products.
With this product, women with pelvic floor disorders can enjoy a better lifestyle without the need for surgery.
In April 2018 Renovia’s first product Leva was approved by the Food and Drug Administration (FDA). Marc Beer has raised an estimated amount of $42 million dollars for Renovia after closing and $10 million in venture debt.